Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 14/20 | 0.38 |
| ▸ | ADCY6 | O43306 | 3/20 | 0.38 |
| ▸ | ADCY3 | O60266 | 3/20 | 0.38 |
| ▸ | ADCY9 | O60503 | 3/20 | 0.38 |
| ▸ | ADCY5 | O95622 | 3/20 | 0.38 |
| ▸ | ADCY8 | P40145 | 3/20 | 0.38 |
| ▸ | ADCY7 | P51828 | 3/20 | 0.38 |
| ▸ | ADCY2 | Q08462 | 3/20 | 0.38 |
| ▸ | ADCY1 | Q08828 | 3/20 | 0.38 |
| ▸ | ADCY4 | Q8NFM4 | 3/20 | 0.38 |
| ▸ | GCG | P01275 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6917341 | 0.87 | GCGR (0.35) | GCGRGCG | |
| SCHEMBL6913807 | 0.81 | GCG (0.34) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL2647806 | 0.71 | GCGR (0.44) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL2647241 | 0.71 | GCGR (0.38) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL2653941 | 0.71 | GCGR (0.50) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL2648467 | 0.71 | GCG (0.53) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL6914041 | 0.70 | GCGR (0.36) | GCGR | |
| SCHEMBL2648927 | 0.69 | GCGR (0.48) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL2659187 | 0.69 | GCGR (0.66) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL2653029 | 0.69 | GCGR (0.53) | GCGRADCY6ADCY3ADCY9ADCY5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463715-A1 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-10-06 | — | — | EP | disclosed |
| US-6762318-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION | NOVO NORDISK A/S (DK) | 2004-07-13 | — | — | US | disclosed |
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | PFIZER INC | 2003-12-25 | — | — | US | disclosed |
| WO-2003048109-A1 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | GPR119, GLP1R, GIPR | GCGR 4/4885ADCY6 1234/4885ADCY3 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.